行情

PLX

PLX

PROTALIX生物疗法
AMEX

实时行情|Nasdaq Last Sale

1.380
-0.020
-1.43%
盘后: 1.390 +0.01 +0.72% 17:26 09/28 EDT
开盘
1.370
昨收
1.400
最高
1.420
最低
1.360
成交量
47.87万
成交额
--
52周最高
7.02
52周最低
1.280
市值
6,286.82万
市盈率(TTM)
-2.7187
分时
5日
1月
3月
1年
5年
Protalix BioTherapeutics 宣布关闭私人票据交换
CARMIEL, , /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ...
PR Newswire - PRF · 08/26 10:50
PLX:债务到期已解决
By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT
Benzinga · 08/22 09:21
Protalix BioTherapeutics Q2 EPS 同比下降 $(0.25) 美元
Protalix BioTherapeutics (AMEX:PLX) reported quarterly losses of $(0.25) per share. This is a 92.31 percent decrease over losses of $(0.13) per share from the same period last year.
Benzinga · 08/16 10:51
Protalix BioTherapeutics 报告 2021 年第二季度财务业绩以及财务和业务更新
Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein ex...
PR Newswire · 08/16 10:50
Protalix BioTherapeutics 宣布私人票据交换
CARMIEL, , /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx®...
PR Newswire - PRF · 08/13 10:50
Protalix BioTherapeutics 将于 2021 年 8 月 16 日发布 2021 年第二季度财务业绩并提供财务和业务更新
Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein ex...
PR Newswire · 08/09 11:15
Protalix 股票在满足 FDA 对法布里病候选申请的要求后交易更高
Benzinga · 08/02 12:03
Protalix Bio 就法布里病中的 PRX-102向 FDA 提交 A 类会议请求
Protalix BioTherapeutics (NYSE:PLX) perks up 2% premarket after submitting Type A Meeting request to the FDA to discuss the Complete Response Letter (CRL) dated April 27, 2021 regarding the Biologics License Application for
Seekingalpha · 08/02 11:07
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解PLX最新的财务预测,通过PLX每股收益,每股净资产,每股现金流等数据分析PROTALIX生物疗法近期的经营情况,然后做出明智的投资选择。
分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

0.00%强力推荐
100.00%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测PLX价格均价为9.75,最高价位12.50,最低价为7.00。
最高12.50
均价9.75
最低7.00
现价1.380
EPS
实际EPS
预期EPS
-0.20-0.14-0.09-0.04
Q3 2020
Q4 2020
Q1 2021
Q2 2021
Q3 2021
机构持股
总机构数: 32
机构持股: 1,241.20万
持股比例: 27.25%
总股本: 4,555.66万
类型机构数股数
增持
6
151.35万
建仓
7
167.01万
减持
3
8.92万
平仓
9
23.20万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-3.50%
制药与医学研究
-1.90%
高管信息
Chairman/Director
Zeev Bronfeld
President/Chief Executive Officer/Director
Dror Bashan
Chief Financial Officer/Senior Vice President
Eyal Rubin
Senior Vice President
Einat Almon
Senior Vice President
Yaron Naos
Vice President - Research & Development
Yael Hayon
Director
Pol Boudes
Director
Gwen Melincoff
Independent Director
Amos Bar-Shalev
Independent Director
David Granot
Independent Director
Aharon Schwartz
暂无数据
PLX 简况
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system (ProCellEx). The Company has developed taliglucerase alfa (marketed under the name Uplyso in Brazil and certain other Latin American countries and Elelyso in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company's product pipeline includes PRX-102 for the treatment of Fabry disease; AIR DNase (PRX-110) for Cystic Fibrosis, and Oral Anti-TNF (OPRX-106) Anti Inflammatory. PRX-102 or alpha-GAL-A is an enzyme replacement therapy product for the treatment of Fabry disease. AIR DNase is a plant cell recombinant human Deoxyribonuclease 1. Oral Anti-TNF represents a mode of administering a recombinant anti-TNF protein.

微牛提供Protalix Biotherapeutics Inc(AMEX-PLX)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的PLX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易PLX股票基本功能。